Hormone receptor positive HER2 negative breast cancer
Not recruitingStudy on Abemaciclib, Letrozole, and Fulvestrant for Patients with Advanced HR-positive/HER2-negative Breast Cancer
Study on Abemaciclib, Letrozole, and Fulvestrant for Patients with Advanced HR-positive/HER2-negative Breast Cancer
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:FulvestrantLetrozole+1
Spain- Participants:18–64 years · 65+ years
- Substances:Fulvestrant
- Sponsor:Medica Scientia Innovation Research S.L.













